Physician profile
Gregory Matthew Gressel
NPI 1972895092
$85,271.94
in general payments reported to CMS, 2019-2025
12 companies · $20K in 2025
The $20K reported for 2025 was more than what 99% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.03 · 2021: $425 · 2022: $2,628 · 2023: $17K · 2024: $45K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $32K · Consulting Fee: $27K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Travel and Lodging: $5,929 · Food and Beverage: $2,072.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $31,668.75 |
| Consulting Fee | $26,587.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,900.00 |
| Travel and Lodging | $5,929.32 |
| Food and Beverage | $2,071.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $46,473.23 | 2021-2025 | |
| Glaxosmithkline, LLC. | $16,817.06 | 2021-2025 | Zejula, Jemperli |
| Astrazeneca Pharmaceuticals Lp | $9,154.67 | 2021-2025 | Enhertu, Onglyza |
| Abbvie INC. | $5,175.77 | 2024-2025 | |
| Pfizer INC. | $5,155.71 | 2024-2025 | |
| Seagen INC. | $2,191.76 | 2021-2023 | Tivdak |
| Baxter Healthcare | $133.17 | 2022-2023 | Seprafilm |
| Immunogen, INC. | $70.47 | 2024 | Elahere |
| Tesaro, INC. | $61.03 | 2019 | |
| Clovis Oncology, INC. | $20.01 | 2022 | |
| Myriad Genetic Laboratories, INC. | $19.06 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Gressel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.